Tenaya Therapeutics' (TNYA) Buy Rating Reiterated at Chardan Capital

Key Points

• Chardan Capital has reiterated a "buy" rating for Tenaya Therapeutics (NASDAQ:TNYA) with a price target of $9.00, while HC Wainwright also maintained a "buy" rating but with a lower target of $5.00.
• Tenaya Therapeutics has a market capitalization of $114.52 million and reported earnings of ($0.14) per share, exceeding consensus estimates of ($0.20) for the quarter.
• The company's stock has been influenced by institutional investments, with approximately 90.54% of the shares owned by institutional investors.

Chardan Capital reaffirmed their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA - Free Report) in a research report released on Thursday morning,Benzinga reports. Chardan Capital currently has a $9.00 target price on the stock.

Separately, HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, April 25th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $6.25.

Tenaya Therapeutics Trading Up 0.2%

Shares of TNYA stock traded up $0.00 during trading on Thursday, hitting $0.67. The company's stock had a trading volume of 1,082,827 shares, compared to its average volume of 2,753,038. The business has a fifty day moving average of $0.67 and a 200-day moving average of $0.67. Tenaya Therapeutics has a 52 week low of $0.36 and a 52 week high of $4.01. The company has a market cap of $109.19 million, a PE ratio of -0.69 and a beta of 3.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.06. As a group, research analysts predict that Tenaya Therapeutics will post -1.35 EPS for the current year.

Hedge Funds Weigh In On Tenaya Therapeutics

Several large investors have recently bought and sold shares of TNYA. Savant Capital LLC bought a new position in Tenaya Therapeutics during the second quarter valued at approximately $52,000. CWM LLC increased its stake in shares of Tenaya Therapeutics by 25.2% in the 2nd quarter. CWM LLC now owns 90,087 shares of the company's stock valued at $55,000 after acquiring an additional 18,142 shares during the last quarter. Woodline Partners LP increased its stake in Tenaya Therapeutics by 30,563.2% during the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock worth $3,373,000 after purchasing an additional 5,896,873 shares in the last quarter. AQR Capital Management LLC acquired a new position in Tenaya Therapeutics during the 1st quarter worth approximately $442,000. Finally, DAFNA Capital Management LLC acquired a new stake in Tenaya Therapeutics during the 1st quarter valued at $27,000. Institutional investors and hedge funds own 90.54% of the company's stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.